Caricamento...
Research progress in immune checkpoint inhibitors for lung cancer in China
Immune checkpoint inhibitors (ICIs) have come to play an increasingly prominent role in the treatment of lung cancer, and some are recommended as a first-line treatment for late-stage non-small-cell lung cancer, either as a monotherapy or in combination with chemotherapy. Accordingly, the indication...
Salvato in:
| Pubblicato in: | Ther Adv Med Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8295948/ https://ncbi.nlm.nih.gov/pubmed/34349843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211029826 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|